Human iPSC-derived gastric antrum organoids for pharmacological modeling of gastric dysmotility-like alterations
This study establishes a human iPSC-derived gastric antrum organoid platform capable of modeling loperamide-induced dysmotility-like alterations and evaluating the partial restorative effects of the prokinetic drug mosapride through morphological, molecular, and transcriptomic analyses.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human stomach is more than a simple bag for holding food; it is a complex engine that must churn, mix, and push contents forward with precise timing. This movement, known as motility, relies on a delicate network of muscle cells and specialized pacemaker cells that generate rhythmic electrical signals. When this system falters, the stomach may empty too slowly, leading to conditions like gastroparesis, where patients suffer from nausea, bloating, and pain. Understanding why this happens and testing new drugs to fix it has long been difficult because human stomach tissue is hard to obtain in a lab, and animal models often fail to mimic human biology accurately. Scientists have recently turned to a powerful tool: growing tiny, three-dimensional versions of human organs from stem cells. These miniature structures, called organoids, can be coaxed to develop into specific parts of the digestive tract, offering a new window into how human tissues behave and respond to medicine.
In a recent study, researchers at the Korea Institute of Toxicology created a specific type of these miniature organs: human gastric antrum organoids. The antrum is the lower part of the stomach responsible for grinding food and pushing it toward the small intestine. By starting with human induced pluripotent stem cells, which can become any cell type in the body, the team guided them through a step-by-step process to form these stomach-like structures. Over the course of about a month, the cells organized themselves into hollow spheres that contained the same types of cells found in a real human stomach, including those that secrete mucus and the specialized cells that help control muscle movement. The researchers confirmed that these tiny organs possessed the molecular signatures of a healthy stomach antrum, including the presence of key proteins that allow cells to communicate and contract.
To test if these organoids could model a real disease, the scientists exposed them to loperamide, a common medication used to stop diarrhea that works by slowing down gut movement. When the organoids were treated with a specific dose of 100 micromolar loperamide for two days, they began to shrink, and the hollow space inside them, called the lumen, became significantly smaller. This physical change mimicked the sluggishness seen in gastric dysmotility. The researchers observed that this shrinking was not just a sign of the cells dying, as a higher dose caused severe damage, but a specific response to the drug. At the molecular level, the treated organoids showed a drop in the expression of genes related to muscle function and nerve signaling, while genes associated with stress and immune responses increased. This confirmed that the drug was altering the very machinery that drives stomach movement.
The team then asked if a drug designed to speed up the stomach could reverse these effects. They treated the shrinking organoids with mosapride, a medication that stimulates gut motility, for four days after the initial drug exposure. While the organoids did not fully return to their original size, the treatment showed a clear trend toward slowing down the shrinkage. More importantly, at the genetic level, mosapride helped reverse some of the changes caused by loperamide. Specifically, it brought down the levels of a stress-related gene that had spiked during the drug exposure and nudged the expression of muscle and nerve genes back toward a healthier state. This suggested that the organoids could not only mimic the problem but also respond to a corrective treatment.
The study provides a new, human-relevant platform for studying stomach movement disorders. By using these stem-cell-derived organoids, scientists can now observe how drugs affect human stomach tissue in a controlled setting, something that was previously very difficult to do. The researchers found that while the organoids did not perfectly restore the tissue to its original state, they did capture the essential biological responses to both the problem and the potential solution. This work suggests that these miniature stomachs could become a valuable tool for testing new therapies for conditions where the stomach fails to move food properly, offering a path forward for developing treatments that are tailored to human biology.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.